PDF factsheet
      Z

cholesterol lowering intervention in post myocardial infarction for all type of patients, clinical trials results

atorvastatin high dose versus atorvastatin
TNT, 2005
NCT00327691
80 mg of atorvastatin daily
versus
10 mg of atorvastatin daily
Chronic coronary artery disease LDL cholesterol < 3.4 mmol/Ldouble blind
Follow-up duration: 4.9 years
14 countries
atorvastatin high dose versus lovastatin
Vascular basis, 2005
atorvastatin (80 mg) with or without vitamin C and E
versus
low dose lovastatin (5 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1 year
atorvastatin high dose versus pravastatin
REVERSAL, 2004
atorvastatin 80 mg daily
versus
Pravastatin(40 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1.5 years
SAGE, 2007
atorvastatin 80 mg daily
versus
pravastatin(40 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1 years
atorvastatin high dose versus simvastatin
IDEAL, 2005
NCT00159835
atorvastatin 80mg daily
versus
simvastatine 20mg/j
Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelinesopen
Follow-up duration: 4.8 years
Denmark, Finland, Iceland, Netherlands, Norway, Sweden
bezafibrate versus placebo
BECAIT, 1996
bezafibrate 200 mg three times daily
versus
placebo
dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the eventdouble blind
Follow-up duration: 5.0 years
Sweden
BIP, 2000
bezafibrate 400 mg/d
versus
placebo
patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL double blind
Follow-up duration: 6.2 y
Israel
clofibtate+niacin versus placebo
Carlson (Stockholm), 1977
clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily
versus
control
survivors of a myocardial infarction below 70 years of age open
Follow-up duration: 5 years
Sweden
ezetimibe versus placebo (on top statins)
IMPROVE-IT, 2014
NCT00202878
10 mg/day of ezetimibe and 40 mg/day of simvastatin
versus
simvastatin 40 mg/day
subjects with stabilized high-risk acute coronary syndrome double blind
Follow-up duration: 5.68 years
39 countries
gemfibrozil versus placebo
VA-HIT, 1999
NCT00283335
gemfibrozil 1.2g daily
versus
placebo
men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or lessdouble blind
Follow-up duration: 5.1 years
USA
low fat diet versus mediterranean-style diet
Tuttle, 2008
low-fat
versus
Mediterranean-style diets
First MI survivorsopen
Follow-up duration: 24 months
pravastatin versus placebo
CARE, 1996
pravastatin 40 mg/d
versus
placebo
men and women with myocardial infarction who had plasma totalcholesterol levels below 240 mg per deciliter (mean,209) and low-density lipoprotein (LDL) cholesterollevels of 115 to 174 mg per deciliterdouble blind
Follow-up duration: 5 years
USA, Canada
LIPID, 1998
pravastatin 40 mg/d
versus
placebo
patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/Ldouble blind
Follow-up duration: 6.1 years
Australie et Nouvelle ZĂ©lande
PACT, 2004
pravastatin initiated within 24 hours of onset of synmptoms and for 4 weeks
versus
placebo
patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction <24 hoursdouble blind
Follow-up duration: 30 days
simvastatin versus placebo
4S, 1994
simvastatin 20 or 40 mg/d, target CT between 3 et 5.2 mmol/l
versus
placebo
patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet double blind
Follow-up duration: 5.4 years
Scandinavia

  Options


in first

in second

  Filter